Journal de recherche et de traitement en oncologie

Abstrait

Study of Plasma Endostatin Level in Patients with Acute Myeloid Leukemia

Haggag R, Hussein O, El Moaty HA, Omran A and Ebian H

Background: Endostatin is a broad spectrum angiogenesis inhibitor and may interfere with the proangiogenic action of growth factors.
Methods: To evaluate the prognostic value of endostatin serum level in acute myeloid leukemia (AML), sixty subjects were included in this study, 30 apparently healthy adult subjects as control (group I) and 30 adult patients with newly diagnosed de novo AML (group II). Estimation of serum endostatin level by ELIZA, at the onset of the disease and after 1 month of induction treatment.
Results: Serum endostatin levels varied widely from 2.1 ng/mL to 7.1 ng/mL (median, 4.1 ng/mL), and the median level was higher in patients with AML compared with patients in the control group (2.6 ng/mL; P<0.001). No significant difference was found between pre-and post-treatment in group II (0.23). The overall survival of patients who had pre-treatment endostatin level ≤50% percentile was significantly longer than patients with pre-treatment endostatin level >50% percentile (p=0.007).According to change of endosatin levels, the overall survival of patients with increased endostatin level was significantly longer than patients with decreased endostatin (p=0.03).
Summary/Conclusion: Inhibition of the angiogenesis may have a role in remission of AML patients.